pinealon

This in vitro study demonstrated that synthetic Pinealon (Glu-Asp-Arg) produces dose-dependent restriction of reactive oxygen species accumulation in cerebellar granule cells, neutrophils, and PC12 pheochromocytoma cells under both receptor-dependent and receptor-independent oxidative stress. Pinealon simultaneously decreased necrotic cell death measured by propidium iodide testing. The protective effects correlated with delayed ERK 1/2 activation timing and cell cycle modifications. Critically, ROS restriction and mortality reduction saturated at lower Pinealon concentrations, while cell cycle modulation continued at higher concentrations—suggesting dual mechanisms including direct genome interaction beyond antioxidant activity.

Pregnant rats with experimental hyperhomocysteinemia (induced by dietary methionine loading) were administered Pinealon throughout pregnancy. Offspring from Pinealon-treated mothers demonstrated significantly improved spatial orientation and learning ability in Morris water maze testing compared to methionine-only groups. Cytometric analysis of isolated cerebellar cells revealed Pinealon decreased stationary ROS levels and enhanced neuronal cell survival. Swimming rate increased and platform search latency decreased in Pinealon-treated offspring, suggesting neuroprotective effects against prenatal oxidative stress and NMDA receptor toxicity. Results indicate Pinealon's geroprotective properties extend to protecting the developing brain under metabolic stress conditions.

This comprehensive review analyzed Pinealon (EDR peptide) mechanisms in Alzheimer's disease pathogenesis, focusing on gene expression and protein synthesis regulation. Oral Pinealon administration in 72 traumatic brain injury patients with cerebrasthenia produced improved memory, reduced headache duration/intensity, emotional balance, and enhanced performance efficacy when added to standard therapy. In TBI patients with long-term consequences, EDR peptide decreased correction test errors and increased alpha-index in bioelectric brain activity measurements, indicating stimulated neuroplasticity and integrative neuronal function. The review detailed EDR's effects on MAPK/ERK signaling, apoptotic proteins (caspase-3, p53), antioxidant enzymes (SOD2, GPX1), and PPAR transcription factors relevant to neurodegeneration.

This clinical study evaluated cellular and metabolic geroprotective effects of synthetic tripeptides Pinealon and Vesugen in 32 patients (ages 41-83) with polymorbidity and organic brain syndrome in remission. Pinealon administration improved central nervous system activity and vital organ function, slowing biological aging indicators. Peptides demonstrated anabolic neuroprotective effects without classical antioxidant mechanisms—showing prooxidant activity via chemiluminescence. CD34+ hematopoietic cell markers decreased, indicating hemopoiesis inhibition possibly related to reduced adaptive reaction involvement. Importantly, neither peptide affected chromatin condensation degree, confirming nuclear genetic safety. Researchers recommended Pinealon as an anabolic-type geroprotector for reducing aging rate in patients with vascular or traumatic organic brain syndrome.

Researchers investigated Pinealon's neuroprotective properties in Huntington's disease models using hippocampal neuronal cultures and transgenic mice. In amyloid synaptotoxicity models replicating Alzheimer's pathology, Pinealon completely reversed damage to mushroom dendritic spines in cultures treated with Aβ42 oligomers. In 5xFAD mice exhibiting impaired long-term potentiation starting at 4 months, Pinealon treatment preserved synaptic function. The peptide interfered with dendritic spine elimination mechanisms in both Alzheimer's and Huntington's disease neuronal cultures. Cell culture studies demonstrated Pinealon protected NMDA receptors from homocysteine-induced toxicity more effectively than carnosine at significantly lower concentrations, indicating potent receptor-protective mechanisms beyond simple antioxidant activity.